Timely and relevant thoracic oncology news brought to you by the only true global association dedicated to the multi-disciplinary study of lung cancer.

Timely and relevant thoracic oncology news brought to you by the only true global association dedicated to the multi-disciplinary study of lung cancer.

Narjust Duma

Add ILCN as a preferred source

June 9, 2020

Telehealth Is Not a One-Size-Fits-All Approach

Evolving Standards of Care

By Narjust Duma, MD Posted: June 10, 2020 During the past 8 weeks, we have heard how many of our colleagues and cancer centers are switching to telehealth. Two things are clear during this pandemic. The first is that cancer centers cannot wait—most cancer procedures and treatments are not elective, and our patients need their…
June 8, 2020

Telehealth Successes and Challenges

Evolving Standards of Care

Posted: June 9, 2020 Across specialties, COVID-19 has resulted in increased patient anxiety and decreased in-person appointments. The rapid uptake of telehealth has, for some, widened disparity gaps and been an obstacle in maintaining patient–physician relationships; for others, telehealth has presented an opportunity to provide consistent long-term care to patients in the safety and comfort…
April 6, 2020

Member Stories: Dr. Narjust Duma

Member Stories from the COVID-19 Era

Dr. Narjust Duma—USA Dr. Narjust Duma is a member of the UW Carbone Cancer Center and Assistant Professor of Medicine in the Division of Hematology, Medical Oncology, and Palliative Care. She graduated first in her medical school class at La Universidad Catolica Nordestana in the Dominican Republic. She then completed her internal medicine residency at…

Narjust Duma

Telehealth Is Not a One-Size-Fits-All Approach

Telehealth Successes and Challenges

Member Stories: Dr. Narjust Duma

COCOON’s Prophylactic Regimen Resulted in Decreased Incidence and Severity of Dermatologic-related Adverse Events

MARIPOSA OS Data Confirms Improved Efficacy for Amivantamab Plus Lazertinib in the First Line for EGFR-mutated NSCLC

Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection

Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy

Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC

No “Known” Risk Factors: The Health Consequences of Radiation Therapy

Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging

No PFS, OS Benefit Seen in Final Results from PACIFIC-2

WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers

Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture

A Holistic Approach to Patient Care